Elite Pharmaceuticals, Inc. (ELTP) Net margin 2017–2026
Elite Pharmaceuticals, Inc. (ELTP) net profit margin by fiscal year — reported net income divided by reported revenue.
30.1%FY2026 · since FY2017: 39.5% → 30.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 30.1% | +35.3 pp |
| FY2025 | -5.1% | -40.6 pp |
| FY2024 | 35.5% | +25.1 pp |
| FY2023 | 10.4% | -17.2 pp |
| FY2022 | 27.6% | +7.5 pp |
| FY2021 | 20.0% | +32.5 pp |
| FY2020 | -12.5% | +110.2 pp |
| FY2019 | -122.6% | -73.4 pp |
| FY2018 | -49.2% | -88.8 pp |
| FY2017 | 39.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ELTP financial trends
ELTP RevenueELTP Net incomeELTP Gross profitELTP Gross marginELTP Operating incomeELTP Operating marginELTP Operating cash flowELTP Free cash flowELTP Capital expendituresELTP Return on equityELTP Stock buybacksELTP Dividends paidELTP Total assetsELTP Total liabilitiesELTP Shareholders’ equityELTP overview →